P0161-A double-blind, placebo-controlled study with acute and continuation phase of Quetiapine and Paroxetine in adults with bipolar depression (Embolden II)
S McElroy, AH Young, A Carlsson, B Olausson… - European …, 2008 - cambridge.org
Background and Aims: Evaluate efficacy and tolerability of quetiapine and paroxetine
monotherapy for major depressive episodes in bipolar disorder during an acute 8-week …
monotherapy for major depressive episodes in bipolar disorder during an acute 8-week …
[引用][C] A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)
A Young, S McElroy, W Chang… - The International …, 2008 - search.proquest.com
Objective: Two previous 8-week studies have demonstrated the efficacy of quetiapine in
bipolar depression. The aim of this study was to evaluate the efficacy and tolerability of …
bipolar depression. The aim of this study was to evaluate the efficacy and tolerability of …
Rapid effects of AXS-05, an oral NMDA receptor antagonist, in major depressive disorder: results from two randomized, double-blind, controlled trials
C O'Gorman, A Jones, DV Iosifescu… - Biological …, 2021 - biologicalpsychiatryjournal.com
Background AXS-05 (dextromethorphan-bupropion modulated delivery tablet) is an
investigational, oral, NMDA receptor antagonist with multimodal activity being developed for …
investigational, oral, NMDA receptor antagonist with multimodal activity being developed for …
Lumateperone (ITI− 007) in the treatment of bipolar depression: results from a randomized clinical trial
I D'Souza, S Durgam, A Satlin, RE Davis… - CNS …, 2021 - search.proquest.com
Study Objective Approved treatments for bipolar depression are limited and associated with
a spectrum of undesirable side effects. Lumateperone (lumateperone tosylate, ITI− 007), a …
a spectrum of undesirable side effects. Lumateperone (lumateperone tosylate, ITI− 007), a …
[HTML][HTML] Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
KH Lee, TS Han, C Han, WM Bahk, SJ Lee… - Clinical …, 2023 - ncbi.nlm.nih.gov
Objective This study tried to observe additional benefit of agomelatine (AGO) treatment for
major depressive disorder (MDD) in routine practice. Methods Retrospective chart review …
major depressive disorder (MDD) in routine practice. Methods Retrospective chart review …
Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist in Major …
A Jones, C Streicher, S Alter, T Zachariah… - CNS …, 2023 - search.proquest.com
Background AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational, NMDA
receptor antagonist with multimodal activity being developed for MDD. The …
receptor antagonist with multimodal activity being developed for MDD. The …
Rapid-acting oral drug (Auvelity) for major depressive disorder
Y Khabir, MR Hashmi, AA Asghar - Annals of Medicine and …, 2022 - journals.lww.com
Major depressive disorder (MDD) has been ranked as the third cause of the burden of
disease worldwide in 2008 by WHO, which has projected that this disease will rank first by …
disease worldwide in 2008 by WHO, which has projected that this disease will rank first by …
Morita Therapy for depression (Morita Trial): a pilot randomised controlled trial
HVR Sugg, DA Richards, J Frost - BMJ open, 2018 - bmjopen.bmj.com
Objective To address uncertainties prior to conducting a fully powered randomised
controlled trial of Morita Therapy plus treatment as usual (TAU) versus TAU alone, or to …
controlled trial of Morita Therapy plus treatment as usual (TAU) versus TAU alone, or to …
A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)
SL McElroy, RH Weisler, W Chang… - The Journal of clinical …, 2010 - psychiatrist.com
Objective: The aim of this study was to evaluate the efficacy and tolerability of quetiapine
and paroxetine monotherapy for major depression in bipolar disorder. Method: 740 patients …
and paroxetine monotherapy for major depression in bipolar disorder. Method: 740 patients …